BioGaia AB launches new clinically proven probiotic for colon health

BioGaia AB has introduced BioGaia Colus, a new probiotic formulation aimed at promoting colon health through a strain-specific and targeted delivery approach. This launch expands BioGaia's science-based portfolio of probiotics for adult gut health with a supplement designed for the lower gastrointestinal tract.

The product contains the proprietary probiotic strain L. reuteri BG-R59. According to the company, this new product has been clinically proven effective in two independent randomized, double-blind, placebo-controlled clinical studies. Professor Veronica Ojetti, who served as the principal investigator for one of the clinical studies, noted the product's potential.

BioGaia AB is known for its research-driven approach to probiotic development. The company's existing range includes various products backed by scientific evidence. This latest addition aims to provide consumers with a targeted option for supporting their digestive well-being.

The introduction of BioGaia Colus reinforces BioGaia's commitment to advancing gut health solutions. The company continues to invest in research and development to bring scientifically validated products to the market, addressing specific health needs within the broader population.